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ABSTRACT
Objective: To evaluate benefits of use of ureteral stents in association with cesarean hysterec-
tomy in case of placenta accreta.
Methods: This was a single center, cohort study. Clinical records of singleton pregnancies with
placenta accreta who underwent cesarean hysterectomy were included in the study. For this
study, pregnancies with diagnoses of placenta accreta, increta, or percreta were considered
under the umbrella term of placenta accreta. For all women with placenta accreta, delivery was
planned via cesarean hysterectomy at 340–356 weeks, without any attempt to remove the pla-
centa. Reasons for earlier delivery included vaginal bleeding and spontaneous onset of labor.
The primary outcome was the incidence of unintentional urinary tract injury. Outcomes were
compared in a cohort of women who had planned the placement of ureteral stents and in
those who did not.
Results: Forty-four singleton gestations with confirmed placenta accreta at the time of cesarean
hysterectomy were included in the study. Twenty-four (54.5%) of the included women had the
placing of ureteral stents prior to cesarean, while 20 (45.5%) did not. At histological confirm-
ation, most of them had placenta accreta (17/44, 38.6%), 14 placenta increta (31.8%), and 13
placenta percreta (29.6%). Urinary tract injuries occurred in eight cases (18.2%), six in the
ureteral stents and two in the non-ureteral stents group (25 versus 10%; p¼ .21). All the injuries
were bladder injuries, while no cases of ureteral injury were recorded. All injuries were recog-
nized intraoperatively.
Conclusion: In case of placenta accreta, the use of ureteral stents in association with cesarean
hysterectomy does not reduce the risk of urinary tract injury.
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Introduction
Placenta accreta is a complication of pregnancy char-
acterized by an abnormal adherence of the placenta
to the uterine wall, secondary to a defect in the
decidua basalis [1]. The reported incidence of abnor-
mal placentation is highly variable, ranging from
1:93,000 to 1:111 pregnancies [2]. The incidence of
abnormal placentation is increasing, most likely
related to the increasing rate of cesarean delivery, one
of the most important risk factors for placenta
accrete [3].
Currently, the management options for placenta
accreta include both conservative and hysterectomy
approaches [4–18]. Conservative strategy consists in
leaving the placenta in situ during cesarean delivery
without hysterectomy. The cesarean hysterectomy
approach consists in leaving the placenta in situ dur-
ing the operation and proceeding with hysterectomy
immediately after cesarean delivery [5–10].
Cesarean hysterectomy is the preferred manage-
ment option, but in addition to the risk of severe
hemorrhage is associated with the risk of uninten-
tional urinary tract injury [13]. Therefore, different
techniques, including the use of ureteral stents,
have been described in order to reduce urinary
tract injury during the management of placenta
accreta [4].
The aim of our study was to evaluate the benefits
of the use of ureteral stents in association with cesar-
ean hysterectomy in case of placenta accreta.
CONTACT Gabriele Saccone gabriele.saccone.1990@gmail.com Department of Neuroscience, Reproductive Sciences and Dentistry, School of
Medicine, University of Naples “Federico II”, 5 Pansini, Naples, Italy
 2019 Informa UK Limited, trading as Taylor & Francis Group
THE JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE
https://doi.org/10.1080/14767058.2019.1609935
Materials and methods
Study design
This was a single center, retrospective, cohort study.
Clinical records of singleton pregnancies at risk of pla-
centa accreta because of persistent placenta previa in
the setting of prior cesarean delivery who delivered
by planned cesarean hysterectomy at the University of
Naples “Federico II” (Naples, Italy) from January 2010
to December 2018 were collected in a dedicated data-
base. For this study, pregnancies with the diagnoses
of accreta, increta, or percreta were considered under
the umbrella term of placenta accreta. Only cases with
confirmed placenta accreta at the time of delivery
were included in the study.
In our institution, all women with placenta previa
identified in the second trimester had a follow-up
ultrasound at 32–34 weeks. Only those with prior
cesarean delivery in whom the placenta reached the
level of the internal cervical os at the last ultrasound
examination in the third trimester were considered as
women with persistent placenta previa in the setting
of prior cesarean delivery and therefore at risk of pla-
centa accreta [17,18]. Only singleton gestations with
suspected placenta accreta were included in this
study. Women were included only in case of intraoper-
ative confirmation of placenta accreta and formal
histologic confirmation.
For all women with suspected placenta accreta
delivery was planned via cesarean hysterectomy at
34–356 weeks, without any attempt to remove the
placenta [13]. Reasons for earlier delivery included
vaginal bleeding and spontaneous onset of labor.
Statistical analysis
Statistical analysis was performed using statistical
package for social sciences (SPSS) v. 19.0 (IBM Inc.,
Armonk, NY).
Data are shown as means ± standard deviation (SD),
or as medians (range), or as number (percentage).
Univariate comparisons of dichotomous data were per-
formed with the use of the Chi-square or Fisher exact
test. Comparisons between groups were performed
with the use of the Man–Whitney U test, to test group
medians with range; and with the use of the T-test or
the one-way ANOVA to test group means with SD.
Primary and secondary outcomes were estimated with
multivariate analyses.
We calculated two-sided p-values. A p-value <.05
was considered to indicate statistical significance.
The primary outcome was the incidence of uninten-
tional urinary tract injury. Outcomes were compared
in a cohort of women who had planned the place-
ment of ureteral stents and in those who did not. This
study was reported following the STROBE guide-
lines [19].
Results
Forty-four singleton gestations, met the inclusion crite-
ria and were included in the study.
Twenty-four (54.5%) of the included women had
the placing of ureteral stents prior to cesarean, while
20 (45.5%) did not. At histological confirmation, most
of them had placenta accreta (17/44, 38.6%), 14 pla-
centa increta (31.8%), and 13 placenta percreta
(29.6%). The mean maternal age was about 34 years,
and the mean BMI 27. All women had prior cesarean
delivery, ranged from 1 to 6, with the vast majority,
having two prior cesarean delivery, 16 (16.7%) in the
ureteral stents group, and 12 (60.0%) in the non-
ureteral stents group (Table 1).
Urinary tract injuries occurred in eight cases
(18.2%), six in the ureteral stents and two in the non-
ureteral stents group (25 versus 10%; p ¼ .21). All the
injuries were bladder injuries, while no cases of
ureteral injury were recorded. All injuries were recog-
nized intraoperatively (Table 2).
Discussion
Main findings
In this small, single center, underpowered, retrospect-
ive study, use of ureteral stents in association with
cesarean hysterectomy in women with placenta
accreta did not reduce the risk of urinary tract injury.
The possibility of intraoperative recognition of the
urinary tract injury was also not increased.
The most important limitation of our study is that
this is a retrospective, non-randomized comparison.
We acknowledge that some outcomes, including the
primary outcome, were underpowered; however, they
are fortunately uncommon with a low overall rate.
Since the decision to plan for ureteral stents was at
attending discretion, the outcomes could be influ-
enced due to selection bias. Notably, the placement of
ureteral stents may be beneficial in some conditions
but not in others. For example, placenta accreta with
parametrial invasion has a different risk of ureteral
injury compared with placenta accreta with blad-
der invasion.
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Implication
Placenta accreta is a major contributor to maternal
morbidity and mortality in many countries, including
the USA. The optimal management regimen has yet to
be defined because of the paucity of outcome data in
the literature and the lack of randomized controlled
trials. So far, no large studies aimed to evaluate the
benefits of ureteral stents, have been published.
Scheduled preterm cesarean hysterectomy appears
to be the treatment of choice for women with sus-
pected placenta accrete, as widely demonstrated in
the literature [2,6,20–22]. The 30% urinary tract injury
rate at the time of cesarean hysterectomy for placenta
accreta is significantly higher than the 4.8% rate
reported for hysterectomy performed for gyneco-
logical diseases [20].
However, the placement of ureteral stent place-
ment is not always necessary [6,14,15,21–22] and is
not currently recommended by guidelines [14,15].
However, according to Matsubara et al. [21] knowing
the ureter position during the surgery may give the
surgeon peace of mind, and usually required a few
minutes for an experienced urologist. In our cohort,
ureter stents were placed in the operative theater just
before surgery. Placement the day before is not rec-
ommended because it may cause uterine contractions
requiring emergency surgery [21].
In a recent systematic review, Tam Tam et al. found
that preoperative placement of bilateral ureteral stents
significantly reduced the risk of urinary tract injury
from 18 to 6% [4]. In addition, cystoscopic placement
of the stents has demonstrated to be quickly and eas-
ily accomplished even in an emergency and associated
with relatively minimal risk.
Conclusions
In summary, in the case of placenta accreta, the use of
ureteral stents in association with planned cesarean
hysterectomy does not improve maternal outcome. A
future large multicenter randomized controlled trial is
necessary to confirm findings from this single center
retrospective study.
Table 1. Characteristics of the included women.
Ureteral stents, N¼ 24 No ureteral stents, N¼ 20 p Value
Age 34.1 ± 4.1 34.5 ± 4.9 .82
BMI 26.8 ± 7.0 27.1 ± 8.1 .88
Ethnicity, n (%) .56
White 98% 23 (95.8%) 20 (100%)
Others 2% 1 (4.2%) 0
Prior cesarean deliveries, n (%) .20
1 4 (16.7%) 7 (35.0%)
2 16 (66.6%) 12 (60.0%)
3 3 (12.5%) 0
4 0 0
5 0 1 (5.0%)
6 1 (4.2%) 0
Histological findings, n (%) .31
Placenta accreta 8 (33.3%) 9 (45.0%)
Placenta increta 10 (41.7%) 4 (20.0%)
Placenta percreta 6 (25.0%) 7 (35.0%)
Data are presented as number (percentage), or as mean ± standard deviation. Boldface data, statistically significant.
BMI: body mass index; SD: standard deviation.
Table 2. Primary and secondary outcomes.
Ureteral stents, N¼ 24 No ureteral stents, N¼ 20 p Value
Overall urinary tract injury, n (%) 6 (25.0%) 2 (10.0%) .21
Bladder injury, n (%) 6 (25.0%) 2 (10.0%) .21
Ureteral injury, n (%) 0 0 Not applicable
Combined bladder and ureteral injury, n (%) 0 0 Not applicable
Genitourinary fistula, n (%) 0 0 Not applicable
Intraoperative recognition of the urinary tract injury, n (%) 6 (25.0%) 2 (10.0%) .21
Postoperative recognition of the urinary tract injury, n (%) 0 0 Not applicable
Blood transfusion (units)
RBC 4.0 ± 3.8 2.6 ± 2.1 .12
FFP 3.7 ± 4.4 1.5 ± 1.9 .05
Severe maternal morbidity .42
ICU admission 0 0
Death 0 1 (5.0%)
GA at delivery (weeks) 34.7 ± 2.2 35.4 ± 2.7 .34
Data are presented as number (percentage), or as mean ± standard deviation. GA: gestational age; RBC: red blood cells; FFP: fresh fro-
zen plasma.
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